CJC-1295 without DAC 5mg + IPA 5mg

What is CJC-1295 without DAC 5mg + IPA 5mg?

CJC-1295 without DAC (MOD-GRF 1-29) is a synthetic peptide fragment derived from growth hormone–releasing hormone (GHRH). The “No DAC” version does not contain the Drug Affinity Complex (DAC) modification, resulting in a shorter-acting research analogue. It is commonly paired with Ipamorelin, a synthetic peptide studied in laboratory models for its selective interaction with growth hormone–related signaling pathways. In research environments, this pairing is often referred to as a CJC-1295 / Ipamorelin combo, allowing investigation of coordinated peptide signaling mechanisms. Both peptides are supplied as 5 mg lyophilized powders, typically with purity ≥95%, verified through analytical methods such as HPLC and mass spectrometry. Each peptide belongs to the broader class of synthetic investigational signaling compounds used in controlled laboratory settings.

Product Specifications

CJC-1295 No DAC (MOD-GRF 1-29)

• CAS Number: 863288-34-0
• Chemical Formula: C152H252N44O42
• Subscript Format: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: ~3367.9 g/mol
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
• Synonyms: MOD-GRF(1-29), CJC-1295 without DAC, modgrf
• Structure Type: GHRH analog (non-DAC modified)

Ipamorelin

• CAS Number: 170851-70-4
• Chemical Formula: C38H49N9O5
• Subscript Format: C₃₈H₄₉N₉O₅
• Molecular Weight: ~711.9 g/mol
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Synonyms: Ipamorelin Acetate, IPAM, NNC-26-0161

What are the key features of CJC-1295 without DAC 5mg + IPA 5mg?

This combination is supplied as a blended lyophilized peptide formulation designed for precise laboratory handling and is suitable for in-vitro and preclinical research models. Its key features include the following:

• High analytical purity, typically ≥ 95%
• Lyophilized, laboratory-ready vial configuration
• Synthetic manufacturing for reproducibility
• Investigated for cellular and endocrine research models
• Compatible with standard peptide handling and storage procedures
• Verified using HPLC and MS analysis
• For laboratory research use only

How is CJC-1295 without DAC 5mg + IPA 5mg synthesized?

Both components are produced by controlled solid-phase peptide synthesis (SPPS). This process allows precise assembly of each amino acid residue, ensuring sequence accuracy and reproducibility in laboratory studies. After synthesis, the material undergoes purification through high-performance liquid chromatography (HPLC), followed by mass spectrometry (MS) verification. These analytical steps confirm identity, purity, and structural integrity before packaging. Because the product is used solely for controlled investigative applications, researchers working with CJC-1295 and ipamorelin for research typically rely on synthetic versions rather than fragments derived from natural proteins. This ensures consistency across experiments and predictable physicochemical behavior.

What is CJC-1295 without DAC 5mg + IPA 5mg being studied for? What are its possible benefits?

CJC-1295 without DAC and ipamorelin have been studied in research models for their potential impact on metabolic regulation, cellular growth mechanisms, and neuroendocrine pathways. CJC-1295 fragments without DAC have been examined for effects on short-term signaling cascades. At the same time, ipamorelin has been investigated for its selective interaction with pathways involved in cell repair and energy utilization. These are ongoing areas of laboratory exploration and remain investigational. Research has explored this combination for its potential effects on several biological systems in preclinical models:

• Growth hormone secretion patterns and pituitary function
• Protein synthesis and metabolic processes
• Cellular recovery and regeneration mechanisms
• Neuroendocrine signaling pathways
• Nutrient utilization in model organisms

Because these findings are preliminary and limited to laboratory environments, all potential biological effects remain theoretical and unproven. Research in this area continues to examine how the CJC-1295 ipamorelin combo may influence measurable markers in controlled experiments.

How does CJC-1295 without DAC 5mg + IPA 5mg work in research studies?

In research studies, CJC-1295 without DAC and ipamorelin are investigated for their potential effects on growth hormone through two distinct mechanisms. CJC-1295 without DAC has been studied for its interaction with growth hormone-releasing hormone (GHRH) pathways in laboratory models. It is researched for how it may influence pituitary gland function related to growth hormone secretion. Meanwhile, ipamorelin is investigated for its potential effects through ghrelin-related pathways. These two peptides have shown potential for complementary interaction because they target different biological mechanisms. When combined, researchers examine how these two peptides may produce synergistic effects in preclinical models and cellular experiments. All observations remain limited to controlled laboratory environments and do not represent therapeutic effects or clinical applications.

What dosing information exists for CJC-1295 without DAC 5mg + IPA 5mg?

Because this combination is restricted to scientific use, no standardized dosing guidelines exist. Preclinical research has employed various dosing approaches depending on the study type:

• In vitro cellular assays: 10–100 nM (nanomolar concentrations)
• In vivo murine models: 5–20 µg/kg (micrograms per kilogram body weight)

Note: These represent different measurement systems appropriate to their respective study types. Nanomolar (nM) concentrations apply to cell-based experiments, while micrograms per kilogram (µg/kg) applies to whole-animal dosing. These values vary significantly depending on the research design, experimental endpoints, and laboratory-specific methodology. No human dosing guidelines exist for this research-grade combination.

How should CJC-1295 without DAC 5mg + IPA 5mg be stored and handled?

Lyophilized materials should generally be stored at –20 °C in a sealed, moisture-free environment. Protection from light and repeated freeze–thaw cycles is recommended to maintain structural integrity. After reconstitution with a suitable laboratory-grade solvent, solutions may be stored short-term at 2–8 °C for limited periods based on the laboratory’s own stability evaluations. Long-term storage recommendations are based on standard peptide-handling guidelines, which recommend minimizing exposure to air and temperature fluctuations. Researchers planning to buy CJC 1295 ipamorelin combo for laboratory use typically follow similar storage principles to ensure consistency and reliability during experimental work.

Where can I read more research about CJC-1295 without DAC 5mg + IPA 5mg?

Additional peer-reviewed information can be found in studies exploring peptide analogues, metabolic signaling, and growth-related pathways. Relevant sources include:

1. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
2. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
4. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.